4th Quarter - Report — COHERUS BIOSCIENCES for COHERUS BIOSCIENCES, INC. (2023)

Firm

COHERUS BIOSCIENCES

Client

COHERUS BIOSCIENCES, INC.

Income

—

Expenses

$175,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Lobbyist	Covered position, as disclosed
BEN KENNEY	Director of Strategic Communications and External Affairs, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
AMANDA MAJOR	—
ALI MCBRIDE	—
DAVID SANDERS	Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Security Council (NSC); Office of Management & Budget (OMB); Executive Office of the President (EOP); White House Office; Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS)

Bills named: S. 3311 (118th), S. 2082 (118th)

Government Issues GOV

Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization

Lobbyist	Covered position, as disclosed
BEN KENNEY	CMS, HHS
AMANDA MAJOR	—
ALI MCBRIDE	—
DAVID SANDERS	—

Contacted: Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.